The identification of a variant in SLC5A7 in a patient with congenital myasthenic syndrome (CMS) indicated that the patient had the very rare and severe CMS Type 20 [122], characterised by life-threatening respiratory episodes, which benefit from cholinesterase inhibitors, and potentially, salbutamol. Here, SLC5A7 is linked to Congenital myasthenic syndromes.